RD Biomed, the company behind the innovative reflux diagnostic kit Peptest, has received a significant vote of confidence from its long-term Chinese distributor and partner, Maxhealth.
Maxhealth, China’s leading medical technology incubation platform, has further invested in RD Biomed, acquiring a controlling stake of 51 per cent in the company.
This partnership solidifies Maxhealth’s commitment to revolutionising the field of gastroesophageal reflux disease (GERD) through its medical innovation platform focused on digestive system diseases.
Maxhealth, listed on China’s National Equities Exchange and Quotations (NEEQ) since 2016 and attaining the innovation level in 2020, has become a prominent player in the global medical technology landscape.
With a mission to address unmet clinical needs and advance diagnosis and treatment, Maxhealth integrates the latest advancements in global clinical science. The company fosters transnational collaboration in research and development, working with multinational pharmaceutical companies and innovation institutions to drive cooperative R&D, production, market access, and academic and product marketing efforts.
Headquartered in Wuxi since 2009, Maxhealth has expanded its reach with offices, R&D centres, and factories in Shanghai, Auckland, Shenzhen, Changsha, as well as the UK. The company’s commitment to innovation is evident in its pioneering work in various fields, including digestive medicine for gastro-oesophageal reflux disease and neural rehabilitation robots, which have achieved global recognition for their cutting-edge technology.
The partnership between RD Biomed and Maxhealth holds immense promise for the future of reflux solutions. RD Biomed’s Peptest, a breakthrough diagnostic tool for reflux, aligns perfectly with Maxhealth’s ambition to create the world’s leading solution for gastroesophageal reflux disease. With its extensive expertise in medical innovation and a global network of collaborative partners, Maxhealth also brings immense value to RD Biomed and the development of Peptest.
Tony Miao, the CEO of Maxhealth, expressed his enthusiasm for the partnership, stating: “We believe that Peptest has the potential to transform the diagnosis and treatment of gastroesophageal reflux disease. Our collaboration with RD Biomed aligns with our commitment to pushing the boundaries of medical innovation and providing patients with the best possible care.”
Harvey Dettmar, CEO of RD Biomed, also expressed his excitement, saying: “We are thrilled to have Maxhealth as our partner and majority shareholder. Their expertise and resources will undoubtedly accelerate the development and adoption of Peptest, allowing us to reach even more patients worldwide.”
As Maxhealth plans a higher grade initial public offering (IPO) on the Shanghai Science and Technology Innovation Board (STAR Market), or similar, in the near future, the partnership with RD Biomed stands as a testament to the company’s commitment to groundbreaking medical technology and its unwavering dedication to improving patients’ lives.
Together, RD Biomed and Maxhealth are poised to reshape the landscape of GERD diagnosis and treatment.